congestive heart failure chf epidemiology forecast insight
Congestive Heart Failure (CHF) Insights and Trends
- Based on DelveInsight's assessment in 2025, the 7MM had approximately 21,165,000 diagnosed prevalent cases of heart failure.
- In the 7MM, the US accounted for the highest number of diagnosed prevalent cases of heart failure, with nearly 7,483,000 in 2025.
- Congestive heart failure, is a condition in which the heart cannot pump or fill effectively, leading to inadequate blood supply to the body; it may involve left-sided failure (reduced oxygen delivery) or right-sided failure (impaired filling and fluid buildup, sometimes termed cor pulmonale when linked to pulmonary hypertension), and is characterized by symptoms such as fatigue, shortness of breath, and fluid retention due to structural and functional abnormalities of the heart muscle.
- Heart failure can result from conditions that damage or overwork the heart, impairing its ability to pump or fill effectively; as the heart weakens, harmful substances further worsen function. Key causes include ischemic heart disease (reduced blood flow due to plaque buildup), diabetes, and chronic high blood pressure, along with other cardiac disorders such as arrhythmias, cardiomyopathy, congenital defects, and valve disease, as well as lifestyle and systemic factors like substance abuse, infections, thyroid disorders, and certain supplements.
- In 2025, the number of diagnosed prevalent cases of heart failure in Japan was 5,366,000, which is likely to increase by 2036. The total diagnosed prevalent cases of heart failure in Japan is expected to increase at a positive CAGR during the forecast period, 2022–2036.
CHF Epidemiology Forecast in the United States
- 2025 Incident Cases of CHF: ~21,165,000
- CHF Growth Rate (2026–2036): ~1.9% CAGR
DelveInsight's ‘Congestive Heart Failure – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the brain cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period
|
2022–2036
|
|
Historical Year
|
2022–2025
|
|
Forecast Period
|
2026–2036
|
|
Base Year
|
2026
|
|
Geographies Covered
|
- North America : The US;
- Europe: Germany, France, Italy, Spain and the UK;
- Asia-Pacific: Japan
|
|
CHF Epidemiology CAGR
(Study period/Forecast period)
|
~1.9% (2026-2036)
|
|
CHF Epidemiology Segmentation Analysis
|
Patient Burden Assesment
- Total Diagnosed Prevalent Cases of Heart Failure
- Gender-specific Diagnosed Prevalent Cases of Heart Failure
- Ejection Fraction-specific Cases of Heart Failure
- New York Heart Association (NYHA) Class-specific Cases of Heart Failure
- Type-specific Cases of Heart Failure
- Age-specific Cases of Heart Failure
|
CHF Understanding and Diagnosis
CHF Overview
CHF is a progressive condition in which the heart cannot pump sufficient blood to meet the body’s needs without increased filling pressures, usually due to impaired ventricular systolic or diastolic function, and is classified by left ventricular ejection fraction (LVEF) into reduced (<40%), preserved (≥50%), and mid-range (40–49%) categories. Early symptoms are often subtle and mistaken for aging, but commonly include breathlessness, fatigue, and fluid retention causing pulmonary congestion and peripheral edema. Diagnosis involves clinical assessment along with laboratory tests (including BNP/NT-proBNP), ECG, and imaging such as chest X-ray and echocardiography, which confirms heart failure, measures ejection fraction, and guides staging and treatment decisions.
Further details are provided in the report.
CHF Epidemiology
Key Findings from CHF Epidemiological Analysis and Forecast
- As per Mauro et al. (2023), a significant number of acute heart failure patients (nearly 35–40%) do not have reduced left ventricle ejection fraction (LVEF). Patients with preserved LVEF are usually older (mean age of 75 years) and more frequently female (nearly 60% of patients).
- CHF is the leading hospitalization cause for those over 65, creating substantial clinical and economic burdens. Types of heart failure are based on left ventricular ejection fraction (LVEF): HFrEF (≤40%), HFmrEF (41-49%), and HFpEF (≥50%). With nearly half of patients diagnosed with HFmrEF or HFpEF, effective treatments for these types remain scarce.
- In 2025, there were ~4,597,000 patients affected with HFpEF, ~2,128,000 patient with HFrEF, and ~758,000 with Heart Failure with mildly reduced Ejection Fraction (HFmrEF) in the US.
- Females are more prevalent in Europe for heart failure than male but in the US, the trend is opposite. Among the EU4, the highest number of diagnosed prevalent cases of CHF were found in Germany, followed by France, and Spain, and the lowest number of diagnosed prevalent cases in Italy in 2025.
Scope of the Report
- The report covers a segment of an executive summary, a descriptive overview of CHF, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
CHF Patient Population Forecast
Report Key Strengths
- Epidemiology‑based (epi‑based) Bottom‑up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs
- What are the disease risks, burdens, and unmet needs of brain cancer? What will be the growth opportunities across the 7MM concerning the patient population with brain cancer?
- What is the historical and forecasted brain cancer patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
1 Key Insights
2 Report Introduction
3 Epidemiology Forecast Methodology
4 Executive Summary of Heart Failure
5 Disease Background and Overview
5.1 Introduction
5.2 Causes of Heart Failure
5.3 Signs and Symptoms
5.4 Stages of Heart Failure
5.5 Classification of Heart Failure
5.6 Biomarkers for the Heart Failure
5.7 Diagnosis, Diagnostic Algorithm, and Differential Diagnosis
5.8 Diagnostic Guidelines
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Assumptions and Rationale
6.3 Total Diagnosed Prevalent Cases of Heart Failure in the 7MM
6.4 The United States
6.4.1 Total Diagnosed Prevalent Cases of Heart Failure in the United States
6.4.2 Gender-specific Diagnosed Prevalent Cases of Heart Failure in the United States
6.4.3 Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in the United States
6.4.4 NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in the United States
6.4.5 Type-specific Diagnosed Prevalent Cases of Heart Failure in the United States
6.4.6 Age-specific Diagnosed Prevalent Cases of Heart Failure in the United States
6.5 EU4 and the UK
6.5.1 Total Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK
6.5.2 Gender-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK
6.5.3 Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK
6.5.4 NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK
6.5.5 Type-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK
6.5.6 Age-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK
6.6 Japan
6.6.1 Total Diagnosed Prevalent Cases of Heart Failure in Japan
6.6.2 Gender-specific Diagnosed Prevalent Cases of Heart Failure in Japan
6.6.3 Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in Japan
6.6.4 NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in Japan
6.6.5 Type-specific Diagnosed Prevalent Cases of Heart Failure in Japan
6.6.6 Age-specific Diagnosed Prevalent Cases of Heart Failure in Japan
7 KOL Views
8 Appendix
8.1 Bibliography
8.2 Report Methodology
9 DelveInsight Capabilities
10 Disclaimer
11 About DelveInsight
List of Tables:
List of Table
Table 1 Summary of CHF Epidemiology (2022–2036)
Table 2 Heart Failure Classification based on the New York Heart Association
Table 3 Heart Failure Classification based on the New York Heart Association
Table 4 Heart Failure Classification based on the American College of Cardiology
Table 5 Shift along the Frank-Starling Curve and Its Causes
Table 6 Characteristics of Other Biomarkers for HF
Table 7 Different test for the estimation of the HF
Table 8 History and Physical Examination
Table 9 Key Recommendations for Use of Biomarkers for Prevention, Initial Diagnosis, and Risk Stratification
Table 10 Key Recommendations for Genetic Evaluation and Testing
Table 11 Key Recommendations for Evaluation with Cardiac Imaging
Table 12 Key Recommendations for Invasive Evaluation
Table 13 Classes of Recommendations
Table 14 Recommendations for Measuring Biomarkers in HF
Table 15 Total Diagnosed Prevalent Cases of Heart Failure in the 7MM (2022–2036)
Table 16 Total Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Table 17 Gender-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Table 18 Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Table 19 NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Table 20 Type-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Table 21 Age-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Table 22 Total Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK (2022–2036)
Table 23 Gender-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Table 24 Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK in ‘000s (2022–2036)
Table 25 NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK in ‘000s (2022–2036)
Table 26 Type-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK in ‘000s (2022–2036)
Table 27 Age-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK in ‘000s (2022–2036)
Table 28 Total Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Table 29 Gender-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Table 30 Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Table 31 NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Table 32 Type-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Table 33 Age-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
List of Figures:
List of Figures
Figure 1: Different Condition in Heart Failure
Figure 2: Stages of Heart Failure
Figure 3: Symptoms of Heart Failure
Figure 4: Different Classes of Drug
Figure 5: Total Diagnosed Prevalent Cases of Heart Failure in the 7MM (2022–2036)
Figure 6: Total Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Figure 7: Gender-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Figure 8: Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Figure 9: NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Figure 10: Type-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Figure 11: Age-specific Diagnosed Prevalent Cases of Heart Failure in the US (2022–2036)
Figure 12: Total Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK (2022–2036)
Figure 13: Gender-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK (2022–2036)
Figure 14: Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK (2022–2036)
Figure 15: NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK (2022–2036)
Figure 16: Type-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK (2022–2036)
Figure 17: Age-specific Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK (2022–2036)
Figure 18: Total Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Figure 19: Gender-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Figure 20: Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Figure 21: NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Figure 22: Type-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
Figure 23: Age-specific Diagnosed Prevalent Cases of Heart Failure in Japan (2022–2036)
-market.png&w=256&q=75)
